• -€0.75
  • - €0.75

Tachifludec 10 Orange Sachets

€9.40
€8.65 Risparmio €0.75
Tax included
Brand
Minsan
034358034
100% secure payments
Hurry up! Only 43 item(s) left in Stock!
Quantity

WARNINGS
Patients should be advised not to take other acetaminophen-containing medicines while taking the drug as high doses of acetaminophen can cause serious adverse reactions. Avoid alcohol consumption during treatment. The danger of overdose is in fact greater in patients with liver problems. Instruct the patient to contact their physician before combining warfarin or any other medication. The use of the product is not recommended if the patient is being treated with anti-inflammatories. Consult your doctor before using the product in patients with enlarged prostate gland or occlusive vascular disease (e.g. Raynaud's syndrome). The medicinal product contains 5.9 mmol (135.8 mg) sodium per sachet: to be taken into consideration in patients with impaired renal function or on a low sodium diet; sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Patients with diabetes should take into account the sucrose content within the product when taking more than 2 sachets per day (sucrose> 5g); azo dyes, sunset yellow (E110) which can cause allergic reactions.
PHARMACOTHERAPEUTIC CATEGORY
Analgesics / Paracetamol, combinations.
STORAGE
Store below 25 degrees C. Store in the original container to protect the product from moisture.
CONTRAINDICATIONS / SECONDARY EFFECT
Children and adolescents under the age of 18. Hypersensitivity 'to the active ingredients or to any of the excipients. Patients taking beta-blockers. Patients taking tricyclic antidepressants and those taking or have taken monoamine oxidase inhibitors within the last 2 weeks. Patients with bronchial asthma, pheochromocytoma, narrow-angle glaucoma, or who are taking other sympathetic mimetic medicines at the same time (such as decongestants, appetite suppressants and amphetamine-like psychostimulants). Patients suffering from hepatic or renal insufficiency, diabetes, hyperthyroidism, hypertension and cardiovascular diseases. Paracetamol-based products are contraindicated in patients with manifest insufficiency of glucose-6-phosphate dehydrogenase and in those suffering from severe haemolytic anemia. Severe hepatocellular insufficiency.
NAME
TACHIFLUDEC ADULTS POWDER FOR ORAL SOLUTION ORANGE FLAVOR
EXCIPIENTS
Sucrose, anhydrous citric acid, sodium citrate, corn starch, sodium cyclamate, sodium saccharin, anhydrous colloidal silica, blood orange flavor, sunset yellow (E 110).
SIDE EFFECTS
The following are the undesirable effects organized according to the MedDRA System and Organ classification. The frequency is defined as follows: very common (> = 1/10), common (> = 1/100 to <1/10), uncommon (> = 1/1000 to <1/100), rare (> = 1 / 10,000 to <1/1000), very rare (<1 / 10,000), not known (cannot be estimated from the available data). Disorders of the blood and lymphatic system. Rare: agranulocytosis, leukopenia, thrombocytopenia; not known: anemia. Disorders of the immune system. Rare: allergic reactions, hypersensitivity reactions, anaphylaxis; not known: anaphylactic shock. Metabolism and nutrition disorders. Common: anorexia. Psychiatric disorders. Very rare: insomnia, nervousness, anxiety, restlessness, confusion, irritability. Nervous system disorders. Very rare: tremor, dizziness, headache. Eye disorders. Not known: mydriasis, acute angle-closure glaucoma. Cardiac pathologies. Rare: tachycardia, palpitations. Vascular pathologies. Not known. hypertension. Respiratory, thoracic and mediastinal disorders. Rare: bronchospasm; not known: edema of the larynx. Gastrointestinal disorders. Common: nausea, vomiting; not known: diarrhea, gastrointestinal pathology. Hepatobiliary disorders. Rare: abnormal liver function; not known: liver disease, hepatitis. Skin and subcutaneous tissue disorders. Rare: rash, angioedema; not known: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme or polymorphic. Renal and urinary disorders. Very rare: tubulointerstitial nephritis (after prolonged use of paracetamol in high doses); not known: aggravated renal failure, haematuria, anuria, urine retention. Report any suspected adverse reactions via the Italian Medicines Agency.
PREGNANCY AND BREASTFEEDING
Paracetamol. Epidemiological studies in pregnant women have shown that there are no contraindications to the use of paracetamol when used in the recommended doses, but the administration of the preparation in pregnancy and lactation must take place under the direct supervision of the doctor. Phenylephrine: There are limited data from the use of phenylephrine in pregnancy. The vasoconstriction of the uterine vessels and the reduction of blood flow in the uterus associated with the use of phenylephrine can 'give rise to fetal hypoxia. The use of phenylephrine in pregnancy should be avoided as further information is needed Ascorbic Acid. There are no controlled data on use in pregnancy. The use of ascorbic acid in pregnancy is only recommended when the benefit outweighs the risk. Paracetamol: Paracetamol is excreted in breast milk but in amounts that are not clinically significant. Available published data do not contraindicate its use during lactation. Phenylephrine: there are no data on the excretion of phenylephrine in breast milk nor information on the effects of phenylephrine on breastfed infants. In the absence of available data, the use of phenylephrine should be avoided during lactation. Ascorbic Acid: Ascorbic acid is excreted in breast milk. Effects on breastfed babies are not known. In summary, its use is not recommended during pregnancy and lactation. There is no evidence in non-clinical studies indicating effects of paracetamol on male and female fertility at commonly used clinical doses. The effect of phenylephrine on male and female fertility has not been studied. There is sufficient evidence to indicate the importance of ascorbic acid at different levels in the reproductive process. However, no definitive human data on the clinical potential of vitamin C are available.
INDICATIONS
Short-term treatment of cold and flu symptoms, including mild / moderate pain and fever, when associated with nasal congestion
INTERACTIONS
Paracetamol: the hepatotoxic effect of paracetamol can 'be enhanced by the intake of other drugs active on the liver, such as zidovudine and isoniazid which can inhibit the metabolism of paracetamol. Administration of probenecid before paracetamol decreases the clearance of paracetamol and the urinary elimination of paracetamol sulfate and paracetamol-glucuronide, and increases the half-life of paracetamol itself. Use with extreme caution and under strict control during chronic treatment with drugs that can determine the induction of hepatic monooxygenases or in case of exposure to substances that can have this effect (for example rifampicin, cimetidine, antiepileptics such as glutethimide, phenobarbital, carbamazepine) . Paracetamol increases the half-life of chloramphenicol. The product taken in high doses can enhance the effect of coumarin anticoagulants (warfarin). Metoclopramide and domperidone can increase the absorption of paracetamol, while it is reduced or delayed by cholestyramine and anticholinergics respectively. Phenylephrine: phenylephrine can antagonize the effect of beta-blocking and antihypertensive drugs (including debrisoquine, guanethidine, reserpine and methyldopa) and can enhance the action of monoamine oxidase inhibitors. The simultaneous use of phenylephrine with tricyclic antidepressants or sympathetic mimetic amines may increase the risk of cardiovascular effects. Phenylephrine can interact with digoxin and cardiac glycosides increasing the risk of arrhythmia or heart attack, and with alkaloids (ergotamine and methylsergide) increasing the risk of ergotism. Ascorbic acid: Ascorbic acid can increase the absorption of iron and estrogen. Ascorbic acid is metabolised to oxalate, and can potentially cause hyperoxaluria and kidney stones in patients through crystallization of calcium oxalate in patients who tend to form calcium stones Interference with some laboratory tests Paracetamol administration may 'interfere with the determination of uricaemia (by the phosphotungstic acid method) and with that of blood glucose (by the glucose-oxidase-peroxidase method). Ascorbic acid can interfere in the measurement of blood and urinary parameters (eg urate, glucose, bilirubin, hemoglobin).
DOSAGE
Adults: 1 sachet every 4-6 hours and up to a maximum of 3 sachets in 24 hours. The medicine should not be used for more 'than 3 consecutive days without consulting the doctor. Children and adolescents under 18 years: the use of the drug is not recommended in children and adolescents under the age of 18 years. Method of administration: dissolve the contents of one sachet in a glass of hot or cold water and sweeten as desired. Once dissolved the medicine gives rise to an orange opalescent solution, free of foreign particles and with an orange flavor
ACTIVE PRINCIPLES
Each sachet contains: paracetamol 600 mg, ascorbic acid 40 mg and phenylephrine hydrochloride 10 mg (equal to phenylephrine 8.2 mg).
Angelini
034358034
43 Items

Specific References

chat Comments (0)
No customer reviews for the moment.

Tachifludec 10 Orange Sachets

€9.40 €8.65